Dongcheng Pharmaceuticals' net profit attributable to shareholders in 2025 is 196 million yuan, a year-on-year increase of 6.4%.

On March 25th, Dongcheng Pharmaceutical ( 002675 ) announced its 2025 annual report. The company’s operating revenue was 2.74 billion yuan, down 4.5% year-over-year; net profit attributable to the parent was 196 million yuan, up 6.4% year-over-year; non-recurring net profit attributable to the parent was 180 million yuan, up 126.5% year-over-year; net operating cash flow was 580 million yuan, an increase of 101.9%; EPS ( fully diluted ) was 0.2372 yuan.

In the fourth quarter, the company’s operating revenue was 698 million yuan, down 1.2% year-over-year; net profit attributable to the parent was 46.51 million yuan, up 174.3% year-over-year; non-recurring net profit attributable to the parent, which was a loss of 71.04 million yuan in the same period last year, successfully turned profitable, reaching 45.87 million yuan; EPS was 0.0564 yuan.

As of the end of the fourth quarter, the company’s total assets were 9.22B yuan, an increase of 6.8% compared to the end of the previous year; net assets attributable to the parent were 4.35 billion yuan, a decrease of 2.9% compared to the end of the previous year.

In the 2025 annual report, the company mentioned that its main business operations focus on nuclear medicine and chemical drugs. During the reporting period, the company made several advances in the nuclear medicine field, including the successful approval of the drug listing application for Andyco’s fluorine-18 sodium fluoride injection, and the inclusion of technetium-580M tetrachloropropyl injection into the national basic medical insurance drug list. Additionally, the company actively promotes a full industry chain system from diagnostic nuclear drugs to therapeutic nuclear drugs, focusing on the research and development of tumors and neurodegenerative diseases.

Regarding chemical drugs, the report shows that the company, as a heparin API manufacturer, has a sales network covering more than 40 countries worldwide, with steady progress in raw material drugs and formulations. The company also emphasizes maintaining a leading position in the production and sales of heparin raw materials, with injection products continuously reaching new sales highs. Overall, the company’s main business operations did not undergo significant changes during the reporting period.